Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Net Income towards Common Stockholders (2016 - 2025)

Editas Medicine (EDIT) has disclosed Net Income towards Common Stockholders for 11 consecutive years, with -$25.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 59.58% to -$25.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$197.6 million, a 6.13% increase, with the full-year FY2024 number at -$237.1 million, down 56.38% from a year prior.
  • Net Income towards Common Stockholders was -$25.1 million for Q3 2025 at Editas Medicine, up from -$51.5 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$18.9 million in Q4 2023 to a low of -$75.7 million in Q1 2025.
  • A 5-year average of -$50.2 million and a median of -$51.5 million in 2025 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 600.08% in 2021, then skyrocketed 68.94% in 2023.
  • Editas Medicine's Net Income towards Common Stockholders stood at -$41.4 million in 2021, then crashed by 46.58% to -$60.7 million in 2022, then surged by 68.94% to -$18.9 million in 2023, then crashed by 140.67% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Net Income towards Common Stockholders are -$25.1 million (Q3 2025), -$51.5 million (Q2 2025), and -$75.7 million (Q1 2025).